KCNH2 and familial long QT syndrome: The potential of hERG activators as therapeutics to counteract the effects of drug-induced LQTS is shown by the recent demonstration of suppression of dofetilide-induced torsades de pointes arrhythmia in a dog model (Qile et al., 2019) by this activator.